{
  "@context": {
    "m0": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/poclets/complex_chemical_synapse/M0_ComplexChemicalSynapse.jsonld#",
    "m1core": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M1_CoreConcepts.jsonld#",
    "m1bio": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M1_extensions/biology/M1_Biology.jsonld#",
    "m2": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M2_MetaConcepts.jsonld#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "owl": "http://www.w3.org/2002/07/owl#",
    "xsd": "http://www.w3.org/2001/XMLSchema#",
    "dcterms": "http://purl.org/dc/terms/"
  },
  "@graph": [
    {
      "@id": "m0:ComplexChemicalSynapse",
      "@type": "owl:NamedIndividual",
      "rdf:type": "m0:Poclet",
      "rdfs:label": "Complex Chemical Synapse (5-Pole Model)",
      "rdfs:comment": "Precise, rapid, and temporally controlled synaptic transmission enabling information processing through chemical signaling between neurons. This 5-pole model extends simpler neuromuscular junction models by incorporating neuromodulation and feedback complexity. Demonstrates high-dimensional interdependence where each pole is absolutely required for function.",
      "dcterms:created": "2026-01-22",
      "dcterms:creator": "Echopraxium with the collaboration of Claude AI",
      "owl:versionInfo": "1.0.0",
      "m0:pocletType": "5-Pole Interdependent System",
      "m0:domain": "Neurobiology / Cellular Communication / Neuroscience",
      "m0:principle": "Sequential Chemical Signal Transduction with Feedback Control",
      "m0:physicalBasis": "Neurotransmitter synthesis, storage, release, reception, and termination enabling neural communication",
      "m0:pedagogicalRole": "Comprehensive model for understanding synaptic pharmacology and neurological disease",
      "m0:alternativeNames": [
        "Central Nervous System Synapse",
        "Chemical Synapse (Extended Model)",
        "5-Stage Synaptic Transmission Model"
      ],
      "m0:spatialScale": "Nanoscale to microscale (20 nm cleft to 1 μm active zone)",
      "m0:temporalScale": "Milliseconds (0.5-5 ms transmission time)",
      "m0:poles": [
        {
          "@id": "m0:Pole1_NTSynthesis",
          "@type": "m2:Process",
          "rdfs:label": "Pole 1: Neurotransmitter (NT) Synthesis",
          "m0:metaconceptInstantiation": "m2:Process",
          "m0:location": "Presynaptic neuron cytoplasm",
          "m0:function": "Produce neurotransmitter molecules from precursors",
          "m0:requirements": {
            "enzymes": "Specific biosynthetic enzymes for each NT class",
            "precursors": "Molecular building blocks (amino acids, acetyl-CoA, etc.)",
            "energy": "ATP for enzymatic reactions",
            "cofactors": "Vitamins (B6, B12), metal ions (Fe, Cu)"
          },
          "m0:examples": [
            {
              "NT": "Acetylcholine (ACh)",
              "enzyme": "Choline acetyltransferase (ChAT)",
              "reaction": "Acetyl-CoA + Choline → ACh + CoA"
            },
            {
              "NT": "Dopamine",
              "pathway": "Tyrosine → L-DOPA (tyrosine hydroxylase) → Dopamine (DOPA decarboxylase)"
            },
            {
              "NT": "Serotonin (5-HT)",
              "pathway": "Tryptophan → 5-HTP (tryptophan hydroxylase) → 5-HT (aromatic amino acid decarboxylase)"
            },
            {
              "NT": "GABA",
              "enzyme": "Glutamic acid decarboxylase (GAD)",
              "reaction": "Glutamate → GABA + CO₂"
            },
            {
              "NT": "Glutamate",
              "source": "Krebs cycle intermediates, glucose metabolism"
            }
          ],
          "m0:regulation": {
            "feedback": "End-product inhibition (NT levels regulate synthesis)",
            "transcriptional": "Gene expression of synthetic enzymes",
            "substrate": "Availability of precursors (e.g., dietary tryptophan for serotonin)"
          },
          "m0:tensorFormula": "D⊗F⊗I (Dynamics × Flow × Information)",
          "m0:asfidContribution": {
            "D": "Dynamic enzymatic reactions (timescale: seconds to minutes)",
            "F": "Metabolic flow (precursors → NT)",
            "I": "Genetic/metabolic information controlling synthesis rates"
          },
          "m0:clinicalRelevance": {
            "L-DOPA": "Precursor therapy for Parkinson's disease (crosses BBB, converted to dopamine)",
            "alphaMetylParaTyrosine": "Tyrosine hydroxylase inhibitor (reduces catecholamine synthesis)",
            "dietaryModulation": "Tryptophan loading can increase 5-HT synthesis"
          },
          "m0:interdependence": {
            "towardsPole2": "No synthesis → no NT to store",
            "feedback": "Pole 5 (reuptake) provides recycled NT, reducing synthesis demand"
          }
        },
        {
          "@id": "m0:Pole2_VesicularStorage",
          "@type": "m2:Component",
          "rdfs:label": "Pole 2: Vesicular Storage",
          "m0:metaconceptInstantiation": "m2:Component",
          "m0:location": "Synaptic vesicles in presynaptic terminal",
          "m0:function": "Concentrate and protect NT from enzymatic degradation, enable quantal release",
          "m0:structure": {
            "vesicleType": "Small synaptic vesicles (~40-50 nm diameter)",
            "concentration": "High intravesicular [NT] (~100-500 mM)",
            "quantity": "~200-300 vesicles per active zone, ~10,000 per terminal"
          },
          "m0:vesicularTransporters": [
            {
              "transporter": "VMAT1/VMAT2",
              "substrates": "Dopamine, norepinephrine, serotonin, histamine",
              "mechanism": "H⁺ antiport (exchanges 2H⁺ out for 1 NT in)",
              "energetics": "Driven by V-ATPase proton pump (pH gradient)"
            },
            {
              "transporter": "VAChT",
              "substrate": "Acetylcholine",
              "mechanism": "H⁺ antiport",
              "stoichiometry": "1 ACh in : 2 H⁺ out"
            },
            {
              "transporter": "VGLUT1/2/3",
              "substrate": "Glutamate",
              "mechanism": "Cl⁻ antiport + ΔΨ",
              "notes": "Also requires membrane potential"
            },
            {
              "transporter": "VGAT (VIAAT)",
              "substrates": "GABA, Glycine",
              "mechanism": "H⁺ antiport"
            }
          ],
          "m0:vesiclePool": {
            "readilyReleasablePool": "~5-20 vesicles docked at active zone, immediately fusible",
            "recyclingPool": "~50-100 vesicles, mobilized during moderate activity",
            "reservePool": "~1000s vesicles, recruited during intense activity"
          },
          "m0:tensorFormula": "S⊗I⊗A (Structure × Information × Attractor)",
          "m0:asfidContribution": {
            "S": "Vesicular membrane structure, transporter organization",
            "I": "NT identity and quantity information (quantal content)",
            "A": "Electrochemical gradient attractor (pH ~5.5, ΔΨ ~50 mV)"
          },
          "m0:protection": {
            "mechanism": "Membrane barrier prevents enzymatic degradation by cytoplasmic enzymes",
            "example": "Dopamine protected from MAO (monoamine oxidase) in cytoplasm"
          },
          "m0:quantalRelease": {
            "quantalSize": "~7000-10000 NT molecules per vesicle (ACh at NMJ), variable for CNS",
            "significance": "Vesicular packaging enables digital signaling (quantal increments)"
          },
          "m0:clinicalRelevance": {
            "reserpine": "VMAT2 inhibitor, depletes vesicular monoamines (historical antipsychotic)",
            "tetrabenazine": "VMAT2 inhibitor (Huntington's chorea treatment)",
            "vesamicol": "VAChT inhibitor (research tool, not clinical)"
          },
          "m0:interdependence": {
            "fromPole1": "Depends on NT synthesis for substrate",
            "towardsPole3": "No vesicles → no quantal release",
            "fromPole5": "Vesicle recycling after exocytosis (endocytosis)"
          }
        },
        {
          "@id": "m0:Pole3_ExocytoticRelease",
          "@type": "m2:Process",
          "rdfs:label": "Pole 3: Exocytotic Release",
          "m0:metaconceptInstantiation": "m2:Process",
          "m0:location": "Presynaptic membrane active zone",
          "m0:function": "Release NT into synaptic cleft in response to presynaptic depolarization",
          "m0:trigger": {
            "event": "Action potential arrival",
            "mechanism": "Membrane depolarization opens voltage-gated Ca²⁺ channels (VGCC)",
            "timing": "Ca²⁺ influx within 0.2 ms of depolarization"
          },
          "m0:calciumChannels": {
            "types": "N-type (CaV2.2), P/Q-type (CaV2.1), R-type (CaV2.3)",
            "location": "Clustered at active zones, near docked vesicles",
            "influx": "~1-10 μM local [Ca²⁺] (from ~100 nM baseline)",
            "nanodomains": "Ca²⁺ nanodomains (<100 nm) couple channels to vesicles"
          },
          "m0:SNAREmachinery": {
            "vSNARE": "Synaptobrevin/VAMP (vesicle membrane)",
            "tSNAREs": "Syntaxin-1, SNAP-25 (target/plasma membrane)",
            "complex": "4-helix bundle brings membranes together",
            "energy": "SNARE zippering provides ~35 kBT energy for fusion"
          },
          "m0:calciumSensor": {
            "protein": "Synaptotagmin (Syt1, Syt2)",
            "mechanism": "C2 domains bind Ca²⁺ → membrane insertion → fusion triggering",
            "cooperativity": "~3-5 Ca²⁺ ions required (steep cooperativity)",
            "speed": "Fusion within 60-200 μs of Ca²⁺ binding"
          },
          "m0:regulatoryProteins": {
            "complexin": "Clamps SNARE complex, prevents spontaneous fusion",
            "munc18": "Chaperones syntaxin, essential for fusion",
            "munc13": "Primes vesicles (MUN domain opens syntaxin)",
            "synapsins": "Regulate reserve pool mobilization (phosphorylation-dependent)"
          },
          "m0:releaseProcess": {
            "step1": "Action potential → VGCCs open",
            "step2": "Ca²⁺ influx (~0.2 ms)",
            "step3": "Ca²⁺ binds synaptotagmin",
            "step4": "SNARE complex completes zippering",
            "step5": "Membrane fusion → pore formation",
            "step6": "NT diffuses into cleft",
            "totalTime": "~0.5-1 ms from AP to NT in cleft"
          },
          "m0:releaseProbability": {
            "P_r": "0.1 - 0.9 (synapse-dependent)",
            "factors": "Ca²⁺ sensitivity, readily releasable pool size, release site occupancy",
            "plasticity": "Short-term facilitation/depression modulate P_r"
          },
          "m0:tensorFormula": "D⊗I⊗F⊗A (Dynamics × Information × Flow × Attractor)",
          "m0:asfidContribution": {
            "D": "Rapid fusion dynamics (sub-millisecond)",
            "I": "Ca²⁺ signal encodes AP timing and frequency",
            "F": "Ca²⁺ influx, NT release flow",
            "A": "Ca²⁺ nanodomains as transient attractors"
          },
          "m0:clinicalRelevance": {
            "botulinumToxin": "Cleaves SNARE proteins (synaptobrevin, SNAP-25, syntaxin) → blocks release. Uses: Cosmetic (Botox), dystonia, migraine, spasticity",
            "tetanusToxin": "Cleaves synaptobrevin at inhibitory synapses → disinhibition → spastic paralysis",
            "omegaConotoxin": "Blocks N-type Ca²⁺ channels → reduces release (ziconotide for chronic pain)",
            "baclofen": "GABA_B agonist → inhibits presynaptic Ca²⁺ channels → reduces release"
          },
          "m0:interdependence": {
            "fromPole2": "No vesicles → no release",
            "towardsPole4": "No release → no postsynaptic signal",
            "feedback": "Autoreceptors (Pole 4 variant) modulate Pole 3 via Ca²⁺ channels"
          }
        },
        {
          "@id": "m0:Pole4_PostsynapticReception",
          "@type": "m2:Transducer",
          "rdfs:label": "Pole 4: Postsynaptic Reception",
          "m0:metaconceptInstantiation": "m2:Transducer",
          "m0:location": "Postsynaptic membrane",
          "m0:function": "Detect NT and transduce chemical signal into electrical/biochemical response",
          "m0:receptorTypes": {
            "ionotropic": {
              "description": "Ligand-gated ion channels - fast transmission",
              "timescale": "0.5-5 ms",
              "mechanism": "NT binding → conformational change → channel opening → ion flux",
              "examples": [
                {
                  "receptor": "AMPA receptors",
                  "NT": "Glutamate",
                  "ion": "Na⁺ (primarily), K⁺",
                  "effect": "Depolarization (EPSP)",
                  "kinetics": "Fast (~1 ms rise, ~5 ms decay)"
                },
                {
                  "receptor": "NMDA receptors",
                  "NT": "Glutamate",
                  "ion": "Ca²⁺, Na⁺, K⁺",
                  "unique": "Voltage-dependent Mg²⁺ block, coincidence detector",
                  "effect": "Slow EPSP + Ca²⁺ influx (plasticity trigger)"
                },
                {
                  "receptor": "GABA_A receptors",
                  "NT": "GABA",
                  "ion": "Cl⁻",
                  "effect": "Hyperpolarization (IPSP)",
                  "kinetics": "Fast (~10-50 ms decay)"
                },
                {
                  "receptor": "Glycine receptors",
                  "NT": "Glycine",
                  "ion": "Cl⁻",
                  "effect": "Hyperpolarization (IPSP)",
                  "location": "Spinal cord, brainstem"
                },
                {
                  "receptor": "Nicotinic AChR",
                  "NT": "Acetylcholine",
                  "ion": "Na⁺, K⁺, (Ca²⁺)",
                  "effect": "Depolarization (EPSP)",
                  "subtypes": "Muscle-type (NMJ), neuronal (α4β2, α7)"
                },
                {
                  "receptor": "5-HT3 receptors",
                  "NT": "Serotonin",
                  "ion": "Na⁺, K⁺",
                  "effect": "Depolarization",
                  "unique": "Only ionotropic 5-HT receptor"
                }
              ]
            },
            "metabotropic": {
              "description": "G-protein coupled receptors (GPCRs) - slow, modulatory",
              "timescale": "100 ms - seconds",
              "mechanism": "NT binding → G-protein activation → second messenger cascades",
              "examples": [
                {
                  "receptor": "mGluR1/5 (Group I)",
                  "NT": "Glutamate",
                  "pathway": "Gq → PLC → IP3/DAG → Ca²⁺ release, PKC activation",
                  "effect": "Slow depolarization, increased excitability"
                },
                {
                  "receptor": "mGluR2/3 (Group II)",
                  "NT": "Glutamate",
                  "pathway": "Gi/o → ↓cAMP",
                  "effect": "Presynaptic inhibition (autoreceptors)"
                },
                {
                  "receptor": "GABA_B receptors",
                  "NT": "GABA",
                  "pathway": "Gi/o → ↓cAMP, ↑K⁺ channels (GIRK)",
                  "effect": "Slow hyperpolarization, presynaptic inhibition"
                },
                {
                  "receptor": "D1 receptors",
                  "NT": "Dopamine",
                  "pathway": "Gs → ↑cAMP → PKA activation",
                  "effect": "Modulation of excitability, gene expression"
                },
                {
                  "receptor": "D2 receptors",
                  "NT": "Dopamine",
                  "pathway": "Gi/o → ↓cAMP",
                  "effect": "Presynaptic/postsynaptic inhibition",
                  "clinical": "Target of antipsychotics"
                },
                {
                  "receptor": "5-HT1A receptors",
                  "NT": "Serotonin",
                  "pathway": "Gi/o → ↓cAMP, ↑K⁺ channels",
                  "effect": "Hyperpolarization, anxiolytic effects"
                },
                {
                  "receptor": "5-HT2A receptors",
                  "NT": "Serotonin",
                  "pathway": "Gq → PLC",
                  "effect": "Excitation, hallucinogenic effects (LSD)",
                  "clinical": "Target of atypical antipsychotics"
                },
                {
                  "receptor": "α2 adrenergic",
                  "NT": "Norepinephrine",
                  "pathway": "Gi/o → ↓cAMP",
                  "effect": "Presynaptic inhibition (autoreceptor)",
                  "clinical": "Clonidine (α2 agonist) for ADHD, hypertension"
                },
                {
                  "receptor": "β adrenergic",
                  "NT": "Norepinephrine",
                  "pathway": "Gs → ↑cAMP",
                  "effect": "Increased alertness, memory consolidation"
                },
                {
                  "receptor": "Muscarinic (M1-M5)",
                  "NT": "Acetylcholine",
                  "pathways": "M1/M3/M5 (Gq), M2/M4 (Gi/o)",
                  "effects": "Diverse - cognition, autonomic function",
                  "clinical": "Anticholinergics (atropine), cholinesterase inhibitors"
                }
              ]
            }
          },
          "m0:postsynapticPotentials": {
            "EPSP": {
              "name": "Excitatory PostSynaptic Potential",
              "mechanism": "Cation influx (Na⁺, Ca²⁺) or Cl⁻ efflux",
              "effect": "Depolarization (brings membrane potential toward threshold)",
              "amplitude": "0.1-5 mV (miniature to unitary)",
              "duration": "5-50 ms (AMPA-type)"
            },
            "IPSP": {
              "name": "Inhibitory PostSynaptic Potential",
              "mechanism": "Cl⁻ influx or K⁺ efflux",
              "effect": "Hyperpolarization (moves away from threshold)",
              "amplitude": "0.5-2 mV",
              "duration": "10-100 ms"
            },
            "integration": {
              "temporal": "Successive PSPs summate if arriving within ~10-20 ms",
              "spatial": "PSPs from different synapses summate across dendrite",
              "location": "Axon hillock integrates all PSPs → AP initiation if threshold reached"
            }
          },
          "m0:postsynapticDensity": {
            "structure": "Protein-rich region ~300-400 nm thick opposite active zone",
            "components": "Receptors, scaffolding proteins (PSD-95, Homer, Shank), signaling enzymes",
            "function": "Organize receptor clusters, anchor signaling complexes, enable plasticity"
          },
          "m0:synapticPlasticity": {
            "LTP": {
              "name": "Long-Term Potentiation",
              "mechanism": "NMDA receptor Ca²⁺ influx → CaMKII activation → AMPA receptor insertion",
              "effect": "Increased synaptic strength (learning)",
              "duration": "Hours to days",
              "location": "Hippocampus (memory), cortex, other regions"
            },
            "LTD": {
              "name": "Long-Term Depression",
              "mechanism": "Low-level Ca²⁺ → phosphatases → AMPA receptor endocytosis",
              "effect": "Decreased synaptic strength (forgetting, refinement)",
              "duration": "Hours to days"
            },
            "homeostasis": {
              "mechanism": "Synaptic scaling (global adjustment of receptor numbers)",
              "function": "Maintain network stability despite plasticity"
            }
          },
          "m0:tensorFormula": "S⊗I⊗A⊗D (Structure × Information × Attractor × Dynamics)",
          "m0:asfidContribution": {
            "S": "Receptor structure, postsynaptic density organization",
            "I": "NT concentration encodes presynaptic activity",
            "A": "Membrane potential attractors (resting ~-70 mV, threshold ~-55 mV)",
            "D": "PSP dynamics (rise/decay kinetics)"
          },
          "m0:clinicalRelevance": {
            "antipsychotics": "D2 receptor antagonists (schizophrenia) - haloperidol, risperidone, olanzapine",
            "benzodiazepines": "GABA_A positive allosteric modulators (anxiety, sedation) - diazepam, alprazolam, lorazepam",
            "ketamine": "NMDA receptor antagonist (anesthesia, depression treatment)",
            "LSD": "5-HT2A agonist (hallucinogen)",
            "naloxone": "μ-opioid antagonist (opioid overdose reversal)",
            "atropine": "Muscarinic antagonist (anticholinergic)",
            "curare": "Nicotinic antagonist (muscle relaxant during surgery)",
            "memantine": "NMDA receptor antagonist (Alzheimer's disease)"
          },
          "m0:interdependence": {
            "fromPole3": "No NT release → no receptor activation",
            "towardsPole5": "Receptor activation must be terminated for temporal precision",
            "autoreceptors": "Variant of Pole 4 on presynaptic terminal, modulates Pole 3"
          }
        },
        {
          "@id": "m0:Pole5_SignalTermination",
          "@type": "m2:Regulation",
          "rdfs:label": "Pole 5: Signal Termination",
          "m0:metaconceptInstantiation": "m2:Regulation",
          "m0:location": "Synaptic cleft + presynaptic/postsynaptic membranes",
          "m0:function": "Rapidly remove NT from cleft to enable temporal precision and prevent receptor desensitization",
          "m0:mechanisms": [
            {
              "type": "Reuptake (Primary mechanism for most NTs)",
              "location": "Presynaptic membrane (primarily), glial cells (astrocytes)",
              "transporters": [
                {
                  "name": "SERT (5-HTT)",
                  "substrate": "Serotonin",
                  "mechanism": "Na⁺/Cl⁻ cotransport (symport)",
                  "stoichiometry": "1 5-HT : 1 Na⁺ : 1 Cl⁻",
                  "drugs": "SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram)"
                },
                {
                  "name": "DAT",
                  "substrate": "Dopamine",
                  "mechanism": "Na⁺/Cl⁻ cotransport",
                  "stoichiometry": "1 DA : 2 Na⁺ : 1 Cl⁻",
                  "drugs": "Cocaine (blocker), amphetamine (reverses transporter), methylphenidate (blocker, ADHD)"
                },
                {
                  "name": "NET",
                  "substrate": "Norepinephrine",
                  "mechanism": "Na⁺/Cl⁻ cotransport",
                  "drugs": "SNRIs (duloxetine, venlafaxine), tricyclics (imipramine)"
                },
                {
                  "name": "GAT-1, GAT-2, GAT-3",
                  "substrate": "GABA",
                  "mechanism": "Na⁺/Cl⁻ cotransport",
                  "drugs": "Tiagabine (GAT-1 blocker, antiepileptic)"
                },
                {
                  "name": "EAAT1-5",
                  "substrate": "Glutamate",
                  "mechanism": "Na⁺/K⁺/H⁺ cotransport",
                  "location": "Astrocytes (EAAT1/2), neurons (EAAT3/4)",
                  "importance": "Critical - prevents excitotoxicity"
                },
                {
                  "name": "No specific transporter for ACh",
                  "note": "Acetylcholine is degraded enzymatically (see below)"
                }
              ]
            },
            {
              "type": "Enzymatic Degradation",
              "examples": [
                {
                  "enzyme": "Acetylcholinesterase (AChE)",
                  "substrate": "Acetylcholine",
                  "location": "Synaptic cleft (anchored to basal lamina at NMJ)",
                  "reaction": "ACh → Acetate + Choline",
                  "speed": "~10,000 molecules/second (one of fastest enzymes)",
                  "drugs": "Donepezil, rivastigmine, galantamine (Alzheimer's), neostigmine (myasthenia gravis), sarin/VX (nerve agents)"
                },
                {
                  "enzyme": "Monoamine Oxidase (MAO-A, MAO-B)",
                  "substrates": "Serotonin, dopamine, norepinephrine, tyramine",
                  "location": "Mitochondrial outer membrane (intracellular, not cleft)",
                  "reaction": "Monoamine → Aldehyde + NH3 + H2O2",
                  "drugs": "MAOIs - phenelzine, tranylcypromine (irreversible), selegiline (MAO-B selective, Parkinson's), moclobemide (MAO-A reversible)"
                },
                {
                  "enzyme": "COMT (Catechol-O-Methyltransferase)",
                  "substrates": "Dopamine, norepinephrine, epinephrine",
                  "location": "Postsynaptic neurons, glial cells",
                  "drugs": "Entacapone, tolcapone (Parkinson's, augment L-DOPA)"
                }
              ]
            },
            {
              "type": "Diffusion Away",
              "mechanism": "NT diffuses out of synaptic cleft into extracellular space",
              "significance": "Tertiary mechanism, slower than reuptake/degradation",
              "relevance": "More important for volume transmission (e.g., dopamine in striatum)"
            }
          ],
          "m0:kinetics": {
            "reuptake": "~1-10 ms (fast, primary termination)",
            "enzymaticDegradation": "~1-5 ms (AChE at NMJ, extremely fast)",
            "diffusion": "~10-100 ms (slower, contributes to tail of NT clearance)"
          },
          "m0:importance": {
            "temporalPrecision": "Rapid termination enables millisecond-resolution signaling",
            "preventSaturation": "Avoids receptor desensitization, maintains dynamic range",
            "feedback": "Reuptake recycles NT (reduces Pole 1 synthesis demand)",
            "energyEfficiency": "Recycling is more efficient than de novo synthesis"
          },
          "m0:tensorFormula": "F⊗D⊗A (Flow × Dynamics × Attractor)",
          "m0:asfidContribution": {
            "F": "NT clearance flow (reuptake, diffusion)",
            "D": "Termination dynamics (time constants)",
            "A": "Baseline [NT] attractor (~0 in cleft between transmissions)"
          },
          "m0:clinicalRelevance": {
            "SSRIs": "Serotonin reuptake inhibitors (depression, anxiety) - fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro)",
            "SNRIs": "Serotonin-norepinephrine reuptake inhibitors (depression, pain) - duloxetine (Cymbalta), venlafaxine (Effexor)",
            "cocaine": "Dopamine/norepinephrine reuptake inhibitor (stimulant, highly addictive)",
            "amphetamine": "Reverses DAT, increases dopamine release (ADHD, narcolepsy)",
            "methylphenidate": "DAT blocker (ADHD) - Ritalin, Concerta",
            "donepezil": "Acetylcholinesterase inhibitor (Alzheimer's disease) - Aricept",
            "rivastigmine": "AChE and butyrylcholinesterase inhibitor (Alzheimer's, Parkinson's dementia) - Exelon",
            "galantamine": "AChE inhibitor (Alzheimer's) - Razadyne",
            "MAOIs": "Prevent NT degradation (depression, older class) - phenelzine, tranylcypromine",
            "selegiline": "MAO-B inhibitor (Parkinson's disease)",
            "tricyclics": "Reuptake inhibition + receptor blockade (depression) - imipramine, amitriptyline"
          },
          "m0:interdependence": {
            "fromPole4": "Receptor activation precedes need for termination",
            "towardsPole1": "Reuptake provides recycled NT, reducing synthesis load",
            "towardsPole3": "Rapid termination enables next release cycle"
          }
        }
      ],
      "m0:interdependenceNetwork": {
        "description": "Quintessential high-coupling system - removing ANY pole destroys function",
        "sequentialDependencies": {
          "chain": "Pole1 → Pole2 → Pole3 → Pole4 → Pole5",
          "forward": "Each pole depends on previous pole's output",
          "cyclical": "Pole5 → Pole1 (feedback: reuptake reduces synthesis demand)"
        },
        "criticalCouplings": [
          {
            "coupling": "Pole1 → Pole2",
            "nature": "No synthesis → no NT to store",
            "strength": "Absolute (necessary)"
          },
          {
            "coupling": "Pole2 → Pole3",
            "nature": "No vesicles → no quantal release",
            "strength": "Absolute (necessary)"
          },
          {
            "coupling": "Pole3 → Pole4",
            "nature": "No release → no signal",
            "strength": "Absolute (necessary)"
          },
          {
            "coupling": "Pole4 → Pole5",
            "nature": "No termination → prolonged activation, saturation, loss of temporal precision",
            "strength": "Absolute (necessary for function)"
          },
          {
            "coupling": "Pole5 → Pole3",
            "nature": "Autoreceptors provide negative feedback",
            "strength": "Regulatory (modulatory)"
          },
          {
            "coupling": "Pole5 → Pole1",
            "nature": "Reuptake reduces synthesis demand",
            "strength": "Regulatory (efficiency)"
          }
        ],
        "emergentProperties": {
          "precision": "Millisecond temporal resolution",
          "reliability": "High-fidelity transmission (though probabilistic)",
          "plasticity": "Activity-dependent modification (LTP/LTD)",
          "modularity": "Each pole = druggable target"
        }
      },
      "m0:territorySpace": {
        "description": "Complex chemical synapse as observed neurobiological phenomenon",
        "observer": "Neuroscientist with electrophysiology, microscopy, pharmacology",
        "asfidState": {
          "A": 0.65,
          "S": 0.75,
          "F": 0.90,
          "I": 0.70,
          "D": 0.80
        },
        "stateVector": "|Ω_synapse⟩ = 0.65|A⟩ + 0.75|S⟩ + 0.90|F⟩ + 0.70|I⟩ + 0.80|D⟩",
        "asfidMean": 0.76,
        "norm": 1.65,
        "interpretation": "Good Territory accessibility - measurable with modern neuroscience tools",
        "observables": [
          "NT synthesis rates (enzyme assays)",
          "Vesicle trafficking (fluorescence imaging)",
          "Ca²⁺ transients (calcium imaging)",
          "NT release (amperometry, FM dyes)",
          "Postsynaptic currents (patch clamp)",
          "NT clearance (HPLC, microdialysis)"
        ]
      },
      "m0:mapSpace": {
        "description": "5-Pole Chemical Synapse Model",
        "observer": "Neuroscience educator, pharmacologist",
        "oriveState": {
          "O": 0.85,
          "R": 0.90,
          "I": 0.88,
          "V": 0.90,
          "E": 0.85
        },
        "stateVector": "|M_synapse⟩_ORIVE = 0.85|O⟩ + 0.90|R⟩ + 0.88|I⟩ + 0.90|V⟩ + 0.85|E⟩",
        "oriveMean": 0.876,
        "interpretation": "Excellent Map - highly validated, predictive, actionable",
        "representation": {
          "structure": "5 sequential poles with feedback loops",
          "schematic": "Linear sequence: Synthesis → Storage → Release → Reception → Termination ⤸",
          "abstraction": "Each pole = discrete functional module"
        }
      },
      "m0:epistemicGap": {
        "description": "Difference between Territory (physical synapse) and Map (5-pole model)",
        "calculation": "ΔΘ approximated from ASFID vs ORIVE discrepancy",
        "estimatedGap": 0.25,
        "interpretation": "Small gap (0 < ΔΘ < 0.5) - model captures ~75% of complexity",
        "assessment": "Model is quite good but omits some biological complexity",
        "missingElements": [
          "Glial cells (astrocytes: glutamate uptake, K⁺ buffering, gliotransmitters)",
          "Nanodomains (Ca²⁺ channel-vesicle coupling)",
          "Non-canonical pathways (GPCR transactivation, retrograde signaling)",
          "Structural plasticity (spine morphology, receptor trafficking details)",
          "Stochastic variability (probabilistic release, channel noise)"
        ]
      },
      "m0:metaconceptsMobilized": {
        "total": 22,
        "percentage": 0.38,
        "byCategory": {
          "Structural": ["Component", "Architecture", "Modularity", "Interface"],
          "Dynamic": ["Process", "Dynamics", "Cascade", "Trigger"],
          "Informational": ["Signal", "Code", "Information", "Encoding"],
          "Regulatory": ["Regulation", "Feedback", "Balance", "Homeostasis", "Trade-off"],
          "Relational": ["Interdependence", "Synergy", "Coupling"],
          "Transformational": ["Transducer"]
        },
        "criticalMetaconcepts": [
          {
            "name": "Interdependence",
            "role": "Quintessential - removing any pole destroys function",
            "validation": "Confirmed by pharmacology (block any pole → no transmission)"
          },
          {
            "name": "Process",
            "role": "Each pole is a distinct process in sequence",
            "formula": "D⊗F"
          },
          {
            "name": "Synergy",
            "role": "Five poles together create emergent transmission capability",
            "formula": "A⊗S⊗I"
          },
          {
            "name": "Feedback",
            "role": "Pole 5 → Pole 3 (autoreceptors), Pole 5 → Pole 1 (reuptake)",
            "formula": "F⊗D⊗I"
          },
          {
            "name": "Balance",
            "role": "E-I balance, synaptic homeostasis",
            "formula": "A⊗S⊗F"
          },
          {
            "name": "Trade-off",
            "role": "Speed vs. reliability vs. energy efficiency",
            "formula": "R⊗V⊗E (ORIVE)"
          },
          {
            "name": "Transducer",
            "role": "Pole 4 converts chemical signal to electrical signal",
            "formula": "S⊗I⊗F"
          }
        ]
      },
      "m0:clinicalSignificance": {
        "overview": "Nearly all psychotropic drugs act on one of the 5 poles",
        "drugsByPole": {
          "Pole1": "L-DOPA (Parkinson's), α-methyl-p-tyrosine (research)",
          "Pole2": "Reserpine (historical), tetrabenazine (Huntington's), vesamicol (research)",
          "Pole3": "Botulinum toxin (cosmetic, dystonia), tetanus toxin (pathogen), Ca²⁺ channel blockers (ziconotide), baclofen (spasticity)",
          "Pole4": "Antipsychotics (D2 antagonists), benzodiazepines (GABA_A modulators), ketamine (NMDA antagonist), LSD (5-HT2A agonist), naloxone (opioid antagonist), atropine (muscarinic antagonist), curare (nicotinic antagonist)",
          "Pole5": "SSRIs (depression), SNRIs (depression/pain), cocaine (addictive), amphetamine (ADHD), methylphenidate (ADHD), donepezil/rivastigmine/galantamine (Alzheimer's), MAOIs (depression), tricyclics (depression)"
        },
        "validation": "100+ drugs validated clinically across all 5 poles, billions of patient-years of data"
      },
      "m0:evolutionaryOptimization": {
        "question": "Why 5 poles?",
        "answer": "TSCG analysis reveals: Maximum controllability + minimal redundancy",
        "tradeoffs": {
          "speed": "Fast transmission (0.5-5 ms) requires rapid termination (Pole 5)",
          "reliability": "Vesicular storage (Pole 2) ensures quantal release",
          "energyEfficiency": "Reuptake (Pole 5) recycles NT, reducing synthesis load (Pole 1)",
          "plasticity": "Postsynaptic mechanisms (Pole 4) enable LTP/LTD without changing presynaptic structure",
          "modularity": "Each pole independently druggable, enables fine-grained pharmacological control"
        },
        "conservedAcrossSpecies": "Core 5-pole structure present from C. elegans to humans (~500 My conservation)"
      },
      "m0:validation": {
        "asfidCompleteness": "All 5 dimensions present (A, S, F, I, D) ✅",
        "metaconceptCoverage": "22/58 metaconcepts mobilized (38%) ✅",
        "interdependence": "Quintessential - validated by pharmacology ✅",
        "emergence": "Synaptic transmission emerges from 5-pole interaction ✅",
        "pedagogicalValue": "Universally taught in neuroscience, pharmacology ✅",
        "empiricalValidity": "Century of data, molecular mechanisms confirmed ✅",
        "clinicalValidity": "100+ drugs, billions of patient-years ✅",
        "frameworkFit": "Perfect M3→M2→M1bio→M0 instantiation ✅"
      },
      "m0:futureExtensions": {
        "6PoleModel": {
          "addPole": "Pole 6: Glial Modulation",
          "components": "Astrocytes (glutamate uptake, K⁺ buffering, gliotransmitters), Microglia (synaptic pruning)",
          "prediction": "Would increase ORIVE (more explanatory power) but also complexity"
        },
        "multiScaleModel": {
          "nanoscale": "Liquid-liquid phase separation, single-molecule tracking",
          "mesoscale": "Synaptic plasticity, spine dynamics, receptor trafficking",
          "networkScale": "Circuit dynamics, oscillations, synchronization"
        }
      },
      "rdfs:seeAlso": [
        "m1bio:Synapse",
        "m1bio:SignalTransduction",
        "m1bio:Neurotransmitter",
        "m2:Process",
        "m2:Interdependence",
        "m2:Synergy",
        "m2:Feedback",
        "m2:Balance",
        "m2:Trade-off"
      ],
      "dcterms:references": [
        "Loewi, O. (1921). Über humorale Übertragbarkeit der Herznervenwirkung. Pflügers Archiv, 189(1), 239-242.",
        "Katz, B. (1969). The Release of Neural Transmitter Substances. Liverpool University Press.",
        "Südhof, T.C. (2013). Neurotransmitter release: The last millisecond in the life of a synaptic vesicle. Neuron, 80(3), 675-690.",
        "Rothman, J.E. (2014). The principle of membrane fusion in the cell. Nature Medicine, 20(2), 129-135.",
        "Kandel, E.R., et al. (2021). Principles of Neural Science (6th ed.). McGraw-Hill.",
        "Nestler, E.J., Hyman, S.E., Malenka, R.C. (2015). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3rd ed.). McGraw-Hill.",
        "Stahl, S.M. (2021). Stahl's Essential Psychopharmacology (5th ed.). Cambridge University Press."
      ]
    }
  ]
}
